Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14420088 | 0.85 | NLRP3 (0.47) | KDM4EL3MBTL1TDP1NLRP3PTGS2 | |
| SCHEMBL30522283 | 0.85 | CTBP2 (0.51) | KDM4EL3MBTL1ALDH1A1HPGDLMNA | |
| SCHEMBL265432 | 0.85 | CTBP2 (0.51) | KDM4EL3MBTL1ALDH1A1HPGDLMNA | |
| SCHEMBL2981629 | 0.84 | ALDH1A1 (0.50) | KDM4EALDH1A1GLAHPGDLMNA | |
| SCHEMBL13988592 | 0.84 | ALDH1A1 (0.45) | KDM4ENLRP3PTGS2ALDH1A1GLA | |
| SCHEMBL3678822 | 0.84 | NLRP3 (0.51) | TDP1NLRP3ALDH1A1LMNAMAPT | |
| Water SCHEMBL27319077 | 0.83 | CTBP2 (0.50) | KDM4EL3MBTL1ALDH1A1HPGDLMNA | |
| SCHEMBL16112668 | 0.82 | P2RX7 (0.45) | KDM4EP2RX7L3MBTL1MAPK1NLRP3 | |
| SCHEMBL8524830 | 0.82 | ESR1 (0.47) | KDM4EALDH1A1GLAHPGDCYP4F2 | |
| SCHEMBL22898417 | 0.82 | KDM4E (0.43) | KDM4EL3MBTL1TDP1NLRP3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114539131-A | Preparation method of fexofenadine hydrochloride | 西安万隆制药股份有限公司 | 2022-05-27 | — | — | CN | claimed |
| US-20020077482-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | MERRELL DOW PHARMACEUTICALS INC. | 2002-06-20 | — | — | US | claimed |
| US-20010020114-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | MERRELL PHARMACEUTICALS INC. | 2001-09-06 | — | — | US | claimed |
| JP-H08512028-A | — | — | 1996-12-17 | — | — | JP | claimed |
| EP-0705245-A1 | NOVEL INTERMEDIATES FOR THE PREPARATION OF ANTIHISTAMINIC 4-DIPHENYLMETHYL/DIPHENYLMETHOXY PIPERIDINE DERIVATIVES | MERRELL PHARMACEUTICALS INC. (US) | 1996-04-10 | — | — | EP | claimed |
| WO-1995000480-A1 | NOVEL INTERMEDIATES FOR THE PREPARATION OF ANTIHISTAMINIC 4-DIPHENYLMETHYL/DIPHENYLMETHOXY PIPERIDINE DERIVATIVES | MERRELL PHARMACEUTICALS INC. (US) | 1995-01-05 | — | — | WO | claimed |
| CN-115745954-A | Preparation method of bilastine intermediate | 山东新时代药业有限公司 | 2023-03-07 | — | — | CN | disclosed |
| EP-1401816-A1 | PROCESS FOR THE PRODUCTION OF THE PIPERIDINE DERIVATIVE FEXOFENADINE | Aventis Pharma Deutschland GmbH (DE) | 2004-03-31 | — | — | EP | disclosed |
| WO-2002102776-A1 | PROCESS FOR THE PRODUCTION OF THE PIPERIDINE DERIVATIVE FEXOFENADINE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020114-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | HRH1, HRH3, HRH4 | KDM4E 3936/4885P2RX7 536/4885L3MBTL1 3787/4885 |
| US-20020077482-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | HRH1, HRH3, HRH4 | KDM4E 3644/4885P2RX7 544/4885L3MBTL1 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.